Evotec AG, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Brendan Smith from TD Cowen maintained a Buy rating on the stock and has a $7.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brendan Smith’s rating is based on a combination of factors that suggest potential long-term growth for Evotec AG. Despite the company’s recent revenue shortfall due to challenges in the Discovery & Preclinical Development segment, there is notable growth in the Just-Evotec Biologics division, which has expanded its customer base and increased revenues by 23% year-over-year. This growth momentum in JEB is seen as a positive counterbalance to the weaknesses in other areas.
Additionally, the upcoming sale of the Toulouse manufacturing facility to Sandoz for over $300 million is expected to strengthen Evotec’s financial position. This transaction not only provides immediate capital but also offers future revenue opportunities through development revenues, milestones, and royalties. The company’s new ‘Restart’ strategy, focusing on capital-efficient models and next-generation innovation, is anticipated to drive long-term growth in high-value sectors, further supporting the Buy rating.